These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3324526)

  • 41. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy.
    Wilmshurst PT; Thompson DS; Juul SM; Jenkins BS; Webb-Peploe MM
    Br Heart J; 1986 Dec; 56(6):544-53. PubMed ID: 3801246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term effect of verapamil in hypertrophic cardiomyopathy.
    Hasin Y; Lewis BS; Lewis N; Weiss AT; Gotsman MS
    Int J Cardiol; 1982; 1(3-4):243-51. PubMed ID: 6807854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment.
    Curtius JM; Stoecker J; Loesse B; Welslau R; Scholz D
    Cardiology; 1989; 76(4):255-63. PubMed ID: 2529965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolution of the electrocardiographic changes in patients with hypertrophic cardiomyopathy.
    Tendera M; Poloński L; Wodniecki J; Kardaszewicz P
    Clin Cardiol; 1991 Nov; 14(11):891-6. PubMed ID: 1764825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Propranolol for severe infantile hemangiomas: follow-up report.
    Sans V; de la Roque ED; Berge J; Grenier N; Boralevi F; Mazereeuw-Hautier J; Lipsker D; Dupuis E; Ezzedine K; Vergnes P; Taïeb A; Léauté-Labrèze C
    Pediatrics; 2009 Sep; 124(3):e423-31. PubMed ID: 19706583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exercise performance in hypertrophic cardiomyopathies.
    Lösse B; Kuhn H; Loogen F; Schulte HD
    Eur Heart J; 1983 Nov; 4 Suppl F():197-208. PubMed ID: 6686536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy.
    Gilligan DM; Chan WL; Joshi J; Clarke P; Fletcher A; Krikler S; Oakley CM
    J Am Coll Cardiol; 1993 Jun; 21(7):1672-9. PubMed ID: 8496536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.
    Rosing DR; Kent KM; Maron BJ; Epstein SE
    Circulation; 1979 Dec; 60(6):1208-13. PubMed ID: 574067
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-term treatment of hypertrophic obstructive cardiomyopathy--usefulness of verapamil.
    Kober G; Schmidt-Moritz A; Hopf R; Kaltenbach M
    Eur Heart J; 1983 Nov; 4 Suppl F():165-74. PubMed ID: 6686532
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of the calcium channel-blocking agents diltiazem and verapamil for treatment of feline hypertrophic cardiomyopathy.
    Bright JM; Golden AL; Gompf RE; Walker MA; Toal RL
    J Vet Intern Med; 1991; 5(5):272-82. PubMed ID: 1836234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol.
    Frank MJ; Abdulla AM; Watkins LO; Prisant L; Stefadouros MA
    Eur Heart J; 1983 Nov; 4 Suppl F():155-64. PubMed ID: 6686531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy.
    Loogen F; Kuhn H; Gietzen F; Lösse B; Schulte HD; Bircks W
    Eur Heart J; 1983 Nov; 4 Suppl F():145-53. PubMed ID: 6686530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Verapamil-induced ventricular tachycardia in hypertrophic cardiomyopathy.
    Wessel A; Seiffert P; Dettmann R; Heintzen PH
    Eur Heart J; 1987 Mar; 8(3):313-5. PubMed ID: 3582389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the ocular safety of verapamil. Scheimpflug photography with densitometric image analysis of lens transparency in patients with hypertrophic cardiomyopathy subjected to long-term therapy with high doses of verapamil.
    Hockwin O; Dragomirescu V; Laser H; Ohrloff C; Kozamanoglu K; Kremer F
    Ophthalmic Res; 1984; 16(5):264-75. PubMed ID: 6541330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study.
    Seiler C; Hess OM; Schoenbeck M; Turina J; Jenni R; Turina M; Krayenbuehl HP
    J Am Coll Cardiol; 1991 Mar; 17(3):634-42. PubMed ID: 1993780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of the effects of propranolol on hypertrophic cardiomyopathy by non-invasive technics].
    Fang WH; Hu ZX; Wang SH; Li JR; Liu YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 1980 Mar; 8(1):13-5. PubMed ID: 7192621
    [No Abstract]   [Full Text] [Related]  

  • 57. The natural history of hypertrophic cardiomyopathy.
    McKenna WJ; Goodwin JF
    Curr Probl Cardiol; 1981 Jul; 6(4):1-26. PubMed ID: 7026177
    [No Abstract]   [Full Text] [Related]  

  • 58. [Beta adrenergic receptors in patients with untreated and verapamil-treated hypertrophic cardiomyopathy].
    Kölbel F; Krulík R; Slíva D; Hradec J; Aschermann M; Simper D; Schreiber V
    Sb Lek; 1988 Jul; 90(7):218-22. PubMed ID: 2851875
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy.
    Edwards RH; Kristinsson A; Warrell DA; Goodwin JF
    Br Heart J; 1970 Mar; 32(2):219-25. PubMed ID: 5462284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of hypertrophic myocardiopathies].
    Bouhour JB
    Presse Med; 1986 Sep; 15(32):1613-4. PubMed ID: 2949206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.